NBIX News Alert Neurocrine Biosciences (NBIX) 21.33 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neurocrine Biosciences (NBIX) 21.33 $NBIX

Shares of NBIX Up 26.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 24, 5:00PM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 26.36% as of today's recent price of $21.33.
NBIX: 21.33 (+0.09)

Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options
at The Street - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Neurocrine Biosciences, Inc. stock, but cautious about paying the going market price of $21.39/share, might benefit from considering selling puts among the alternative strategies at their disposal.
NBIX: 21.33 (+0.09)

Endometriosis - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/36sdmb/endometriosis) has announced the addition of the "Endometriosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Euroscreen - Takeda Pharmaceutical - Neurocrine Biosciences - Astellas Pharma - Kissei Pharmaceutical - SK Chemicals - Bayer AG - Addex Therapeutics Ltd - Evotec AG - ValiRx Plc - Repros Therapeutics Inc. - Dongkook Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Orphagen Pharmaceuticals, Inc. - Peptron, Inc. - PregLem SA - EndoCeutics, Inc. - Isifer AB - ElexoPharm GmbH - APAvadis Biotechnologies Srl - AbbVie Inc. - Forendo Pharma Oy For more information visit http://www.researchandmarkets.com/research/36...ometriosis
NBIX: 21.33 (+0.09), ABBV: 66.21 (+1.86)

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/znzbgg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Aastrom Biosciences - Johnson & Johnson - AstraZeneca - Athersys - GlaxoSmithKline - Gilead Sciences - Merck & Co - Bioheart - Neurocrine Biosciences - Acorda Therapeutics - Les Laboratoires Servier - Bayer - Celladon - IntelGenx - Mesoblast - Palatin Technologies - Cardio3 BioSciences - La Jolla Pharmaceutical - Mast Therapeutics - NeoStem - Cytomedix - Torrent Pharmaceuticals - Juventas Therapeutics - Protemix Corporation - AngioDesign - Cardioxyl Pharmaceuticals - Innopharmax - QUANTUM GENOMICS - ARCA biopharma For more information visit http://www.researchandmarkets.com/research/zn...tive_heart
JNJ: 104.59 (+0.31), NBIX: 21.33 (+0.09), MSTX: 0.46 (unch), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), PTN: 0.71 (+0.04), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)

Neurocrine Biosciences Up 24.1% Since SmarTrend Uptrend Call (NBIX)
Comtex SmarTrend(R) - Wed Dec 17, 11:07AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 24.05% as of today's recent price of $20.94.
NBIX: 21.33 (+0.09)

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), NBIX: 21.33 (+0.09), GILD: 91.29 (+1.84), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), CTIC: 2.36 (+0.05), CEMP: 20.66 (+0.78), BMY: 59.15 (-0.01)

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients
at The Street - Tue Dec 16, 3:06PM CST
Auspex is expected to seek U.S. approval for SD-809 next year.
NBIX: 21.33 (+0.09), ASPX: 49.93 (-0.10)

Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), ACAD: 30.95 (+0.78), NBIX: 21.33 (+0.09), HALO: 9.34 (+0.31)

Nasdaq stocks posting largest percentage increases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SOFO: 7.48 (-0.11), NBIX: 21.33 (+0.09), DERM: 19.65 (+0.38), CHKE: 18.70 (-0.41), LAYN: 10.11 (+0.25), NDQ.TO: 19.67 (+0.60), CLDN: 18.54 (+0.85), NVDQ: 16.90 (+0.55), OBAS: 7.04 (-0.46)

Just Released: New Research on American Airlines, Staples, Cyren, Neurocrine Biosciences, and Cherokee
PR Newswire - Thu Dec 11, 8:17AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only. To access our full PDF reports on a complementary basis, please visit the links below.
NBIX: 21.33 (+0.09)

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/srj257/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Addex Therapeutics - Azevan Pharmaceuticals - Catalyst Pharmaceutical Partners - Humanetics Corporation - Intra-Cellular Therapies - Marinus Pharmaceuticals - Nanotherapeutics - Neuralstem - Neurocrine Biosciences - NeuroNascent - Omeros Corporation - Otsuka Holdings - Pfizer - Polleo Pharma - Tonix Pharmaceuticals Holding - Vanda Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/sr...ttraumatic
NBIX: 21.33 (+0.09), TNXP: 6.18 (-0.09), MRNS: 8.75 (+0.54), CPRX: 2.90 (-0.02), VNDA: 14.69 (+1.11), ITCI: 17.99 (+0.16), OMER: 22.09 (+0.48)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 4:39PM CST

RH: 96.97 (-0.16), BXS: 22.50 (-0.02), NBIX: 21.33 (+0.09), BDC: 80.39 (+0.12), GDP: 4.93 (-0.22), APT: 2.55 (-0.03), AUQ: 3.08 (+0.10), LAKE: 8.94 (+0.07), SFUN: 7.17 (-0.03), AGI: 6.89 (+0.17)

Uptrend Call Working As Neurocrine Biosciences Stock Rises 17.7% (NBIX)
Comtex SmarTrend(R) - Wed Dec 10, 10:00AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.65% as of today's recent price of $19.86.
NBIX: 21.33 (+0.09)

Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
PR Newswire - Wed Dec 10, 7:00AM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. The Company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH, the 1401 Study.
NBIX: 21.33 (+0.09)

Clinovo Presents Its Cloud-Based EDC System ClinCapture at the San Diego Clinical Research Network Event in San Diego
PRWeb - Mon Dec 08, 2:12AM CST
Clinovo presents its cloud-based technology and EDC solution ClinCapture at the San Diego Clinical Research Network event in San Diego on December 9th, 2014. This program provides an introduction to using the cloud in the life sciences and clinical trials.
NBIX: 21.33 (+0.09)

Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Thu Dec 04, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York City.
NBIX: 21.33 (+0.09)

17.3% Return Seen to Date on SmarTrend Neurocrine Biosciences Call (NBIX)
Comtex SmarTrend(R) - Wed Dec 03, 9:22AM CST
SmarTrend identified an Uptrend for Neurocrine Biosciences (NASDAQ:NBIX) on October 16th, 2014 at $16.88. In approximately 2 months, Neurocrine Biosciences has returned 17.30% as of today's recent price of $19.80.
NBIX: 21.33 (+0.09)

Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 12:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.
NBIX: 21.33 (+0.09), DB: 30.95 (+0.04)

Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
Business Wire - Wed Nov 19, 7:01AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company's commercial operations, research activities, business development and compliance with industry standards.
NBIX: 21.33 (+0.09), RTRX: 12.92 (+0.19), AMGN: 160.67 (+3.15)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 105

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 69

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 73

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 107

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 119

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 93

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Mauna Kea Technologies Advances AI Integration in Endomicroscopy

Updated Category News Views 512

Mauna Kea Technologies and its Innovative AI Patent Mauna Kea Technologies, the proud inventor of Cellvizio®, a revolutionary platform that blends probe and needle-based confocal laser endomicroscopy (p/nCLE), has taken a significant step forward in the realm of artificial intelligence in medical diagnostic procedures. Recently, the company announced the granting of a...

Continue Reading
Hot Chili Limited Secures Approval for La Verde Expansion Drilling

Updated Category News Views 168

Hot Chili Limited's Significant Progress at La Verde Hot Chili Limited (OTCQX: HHLKF) has obtained key regulatory approval to enhance the drill coverage of its La Verde copper-gold discovery. This exciting development comes as the company aims to broaden exploration activities in an area strategically important to its operations. Understanding the La Verde Project The La...

Continue Reading
Investors on High Alert as Lithium Faces Growing Demand Challenges

Updated Category News Views 261

The Lithium Debate: Rising Tensions at COP30 At the recent climate discussions, the dialogue took an unexpected turn, raising eyebrows among investors in various clean-tech sectors. For the first time in thirty years of United Nations climate negotiations, serious concerns emerged regarding the social and environmental risks associated with lithium mining, which is...

Continue Reading
Edible Garden Expands USDA Organic Herb Line in New Markets

Updated Category News Views 71

Introducing Edible Garden's Organic Product Line Edible Garden AG Incorporated has been making headlines as a leader in controlled environment agriculture (CEA). Recently, they launched their USDA Organic herb product line at Green’s Natural Foods and The Extra Supermarket, which is a significant step in their mission to provide sustainably grown and organic produce....

Continue Reading
Growth Surge: The Value of $100 Investment in Riot Platforms

Updated Category News Views 148

Understanding the Rise of Riot Platforms Investors seeking substantial growth often look to companies like Riot Platforms (NASDAQ: RIOT), which has demonstrated impressive performance over the past five years. With a remarkable annualized return of 46.95%, Riot has outpaced the market by over 34.28%. This consistent growth contributes to a current market capitalization of...

Continue Reading